Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BANY leavin' da station now!!!
Finally got your board bookmarked shakez - call me a slow learner lol - best to u & all momo playerz
shakerzzz: You won't give 'er back old buddy! She's primed & ready for yet another ride on the momo train!!!
shakerzzz - Hey old buddy!!! Jump on the BANY momo train nowwwwwwwwwwwwzzzzzzzzzzz my man:)
Best to u as always!!!!
Thnx for PDVP as well:)
Thnx pick em but I was hopin' for a link? tia if u can provide
Where's shakerz board? I 4got to add it to my bookmark.
Just loaded up 4 million BANY!!!!!!!!!!!!!!! I smell momo-run there again!!!!!!
NGA ok
Agreed Harry! Everything I touches turns to gooool...oops...chit!
Charlatan: I got me some BANY lol;)
BANY: Impossible fills for me - keep raising it every time I raise my bids lol...gotta jump over 'em now I guess!
DNAG shakin' a little bit
Would someone plz take me to the woodshed & kick me hard a few times! Unbelievable how I allowed DNAG to slip aways! Don't know why I'm so mad about this one but it really bothers me that I didn't load the boat between .008 & .0083!
DNAPrint Pharmaceuticals / Harvard Study Shows PT-401 to Be Three Times More Potent Than Conventional EPOs in Treating Anemia
Internet Wire via COMTEX
Dec 8, 2006 7:00:38 AM
"Important Therapeutic Advantages" Are Suggested; Results to Be Released at American Society of Hematology Annual Meeting
SARASOTA, FL, Dec 08, 2006 (MARKET WIRE via COMTEX News Network) --
DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced the results of preclinical studies conducted by the Company and Harvard Medical School on the Company's proprietary PT-401 protein. The studies demonstrate that PT-401 is three times more effective than conventional EPO treatments, and conclude that PT-401 has "biological activities superior to those of EPO monomer, suggesting important therapeutic advantages."
The results of the study will be formally presented by Drs. Jee-Yeong Jeong and Arthur J. Sytkowski on Dec. 9, 2006, at the American Society of Hematology 48th Annual Meeting and Exposition in Orlando, Fla. Dr. Sytkowski is the Director of the Laboratory for Cell and Molecular Biology at Beth Israel Deaconess Medical Center (BIDMC), an affiliate of Harvard Medical School.
The study's purpose was to determine whether it was possible to develop a more effective erythropoiesis stimulating agent (ESA) than human erythropoietin (EPO, epoetin), which is widely used in the treatment of certain forms of anemia but which has a relatively short in vivo half-life, resulting in considerably high and frequent doses in order to maintain therapeutic effectiveness. The study, conducted over a seven day period using laboratory mice, showed that the "super EPO" that forms the basis for PT-401, and which comprises EPO-dimer and EPO-trimer fusion proteins that were comprised of "head-to-tail" repeats, is up to three times more effective than conventional EPO treatments, exhibiting enhanced biological properties in vitro and in vivo.
"Dr. Sytkowski is one of the foremost scientists in the field of therapeutic protein research, particularly Erythropoietin," stated DNAPrint Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D. "We are proud that our affiliation with Dr. Sytkowski and Beth Israel Deaconess Medical Center has produced this research, which shows the promise of PT-401 in treating chronic anemia due to renal failure, cancer, or other causes."
"This study is an important step in the advancement of PT-401 as a potential competitor in the EPO market, which currently exceeds $10 billion and is rapidly growing," stated DNAPrint Genomics President and Chief Executive Officer Richard J. Gabriel. "This study is just one step, however, and we look forward to continuing our collaboration with Dr. Sytkowski as this project advances."
PT-401 is a "Super EPO," a more powerful erythropoiesis stimulating agent than Erythropoietin, a well-known drug used for the treatment of anemia. Previously, DNAPrint Pharmaceuticals, the Company's wholly owned subsidiary, announced three successful milestones related to PT-401: the use of CHO cell lines, the use of SDS-PAGE, a well-established separation technique for the testing of cell lines, and a specially developed isoelectric focusing (IEF) method. The initial research has been conducted in conjunction with Dr. Sytkowski.
In addition to Dr. Sytkowski, research was carried out with Drs. Jee-Yeong Jeong, Changmin Chen and Kerry L. Davis of the Laboratory for Cell and Molecular Biology, Division of Hematology and Oncology at the Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School.
The study was conducted in conjunction with the UCLA Olympic Analytical Laboratory in the Department of Molecular and Medical Pharmacology at the University of California at Los Angeles and included Drs. Andreas Breidbach and Don H. Caitin.
The study and its results are illustrated in a multi-color poster that Dr. Sytkowski will distribute as part of the presentation.
Ahhhh news on DNAG
What's wakin' DNAG up?
DNAG runnin'
No GHTI fill at .012 for moi!
PGNF meeting today will determine how much mojo it may have in it
I jumped in NMKT
Ok done! Dumped BANY for a wash & not chasin' a thing into close - have a great night all:)
ya very weird - watchin' it for possible gapper
yep but i don't get it?
will do down & I confess to tryin' a small chump changer in BANY at .0055
I traded nada today down! I just couldn't pull the trigger so spent the day scanning mumbling lol. best to u as always!
AXGC!!!!!!!!!!!!!!!!!!
Another excellent day for BANY playerzzz...have a great night all & best of cont'd success!
Runners: Seriously...does it matter if BANY is a POS in POS-land? All that matters is whether or not u can trade it to profits otherwise what's the point? The penny casino & momo tradin' are not about finding the 10% that succeed. It's about finding a POS to trade for profits...'nuff said
Bouncin' off .0063/.0064 area fairly good so far down but I'm a little leery so will probably just wait for tomorrow...best to u as always!
Thursday is the meeting day
down: I keep flipping outta BANY in stages once I'm up 10 points...served me well these past few days:)
Runners: and don't they also have a monster 2B share CD out?
BANY: got a bid at .0067
Mostly due to no follow through. Micro-season means multi-day/multi-bag runs with oodles of follow through;)
BANY: All aboard...8's gettin' hit...penny-land here we come!!!!
EVO: Agreed on BANY & we've all seen what can happen on these blue sky breaks! Bring it on!!! Best to all
BANY goes for break of .008 then a penny after 1pm! The real fun will be what happens when it taps on the penny this time!!!!
BANY: I jumped in for another round trip
BANY gonna break da penny - all aboard;)